M3 (TSE:2413) Stock Price Slides As Profit Pressure Clouds Earnings Power

M3 stock has been under quiet pressure, down about 15% over the past week and roughly 21% over the past month, even as the latest earnings landed with a firmer profit story than the price suggests. The headline this quarter is earnings power. Basic earnings per share for Q1 2027 came in at ¥15.85 with net income of ¥10,579m, while trailing 12 month earnings per share sit at ¥68.45 and a P/E of 21.9x that is close to the Asian healthcare services average.

Is M3 trading at a genuine discount, or is this just a value mirage created by recent earnings strength and a softer share price? See how its current P/E, growth forecasts, and cash flows line up in our valuation analysis for M3

Q1 2027 Earnings Summary

• Revenue, Q1 2027 vs. Q1 2026: ¥90,105m vs. ¥86,200m (up about 4.5%)
• Net Income, Q1 2027 vs. Q1 2026: ¥10,579m vs. ¥11,840m (down about 10.7%)
• Basic EPS, Q1 2027 vs. Q1 2026: ¥15.85 vs. ¥17.44 (down about 9.1%)
• Trailing 12-Month Basic EPS, Q1 2027 vs. Q1 2026: ¥68.45 vs. ¥60.50 (up about 13.1%)

Prefer clear charts instead of another dense wall of earnings tables and ratios? See M3's full visual breakdown, with a focus on its valuation picture, in the company report for M3.

Moderate Support For The Bullish M3 Story

M3 still gives bulls some footing. Revenue in Q1 2027 was ¥90,105m versus ¥86,200m a year ago, so the top line is moving in the right direction for a digital healthcare platform that depends on broad client spend. Trailing 12 month basic EPS is ¥68.45 versus ¥60.50 a year earlier, which indicates earnings capacity over a full year is improving even though the latest quarter is softer. For investors who focus on long term monetisation of M3’s healthcare networks, that mix can still sit comfortably with a constructive view.

Short Term Profit Drift Fuels The Bear Case

The bear story for M3 is getting some support from the nearer term trends. Net income in Q1 2027 of ¥10,579m compares with ¥11,840m a year earlier and basic EPS of ¥15.85 is below ¥17.44. That signals pressure on quarterly profitability even as revenue edges higher. The share price has also fallen about 15% over 7 days and roughly 21% over 30 days as of early August 2026. For cautious investors, that combination can reinforce concerns about margin resilience and execution across M3’s broader healthcare services mix.

With earnings momentum improving but margins slightly softer and the share price under pressure, the real question is whether M3 has the balance sheet strength to absorb more bumps. Check the financial health analysis of M3 stock to verify its cash, debt, and runway.

Stay Ahead With Simply Wall St

If the recent share price pressure alongside M3’s firmer trailing earnings has caught your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch for a potential entry point. After you decide to take a position, use the Portfolio Command Center to cut through day to day noise and focus on the key updates that matter for your holdings. For a longer term view, tap into the Community to see how other investors are thinking about catalysts, risks, and valuation. That mix of tools can help you spot hidden shifts early and stay a step ahead of the market.

Seeking Fresh Alternatives Beyond M3

Markets move fast and the next breakout list does not stay quiet for long. Scan fresh ideas with real momentum before the crowd catches on, then get in early.

• Spot cash generative companies that still trade like overlooked laggards by running the curated 18 high quality undervalued stocks while these potential rebound stories are still under the radar for now.
• Ride the next wave of AI momentum by checking the hand picked 69 profitable AI stocks that aren't just burning cash before valuations run away and the best entry points are gone.
• Lock in potential income streams that others have not yet crowded into by reviewing the carefully filtered 43 dividend fortresses while yields and prices still look appealing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com